These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36029536)

  • 1. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
    Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
    Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
    Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
    PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
    Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
    Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.
    Jo M; Koizumi K; Suzuki M; Kanayama D; Watanabe Y; Gouda H; Mori H; Mizuguchi M; Obita T; Nabeshima Y; Toyooka N; Okada T
    Bioorg Med Chem Lett; 2023 May; 87():129266. PubMed ID: 37011768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminase (GLS1) gene expression in primary breast cancer.
    Vidula N; Yau C; Rugo HS
    Breast Cancer; 2023 Nov; 30(6):1079-1084. PubMed ID: 37679553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol.
    Fu A; Yu Z; Song Y; Zhang E
    Mol Med Rep; 2015 Jun; 11(6):4727-33. PubMed ID: 25625774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting GLS1 to cancer therapy through glutamine metabolism.
    Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
    Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of a novel glutaminase inhibitor.
    Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
    FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Takahashi S; Saegusa J; Sendo S; Okano T; Akashi K; Irino Y; Morinobu A
    Arthritis Res Ther; 2017 Apr; 19(1):76. PubMed ID: 28399896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
    Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase inhibitors: a patent review.
    Wu C; Chen L; Jin S; Li H
    Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Glutaminase by Natural Compounds: Structure-Based Virtual Screening and Molecular Dynamics Simulation Approach to Suppress Cancer Progression.
    Tabrez S; Zughaibi TA; Hoque M; Suhail M; Khan MI; Khan AU
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Glutaminase allosteric inhibitors through drug repurposing and comparative MMGB/PBSA and molecular dynamics simulation.
    Yousaf R; Navid A; Azam SS
    Comput Biol Med; 2022 Jul; 146():105669. PubMed ID: 35654625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer.
    Pan T; Gao L; Wu G; Shen G; Xie S; Wen H; Yang J; Zhou Y; Tu Z; Qian W
    Biochem Biophys Res Commun; 2015 Jan; 456(1):452-8. PubMed ID: 25482439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated patent review of glutaminase inhibitors (2019-2022).
    Wang D; Li X; Gong G; Lu Y; Guo Z; Chen R; Huang H; Li Z; Bian J
    Expert Opin Ther Pat; 2023 Jan; 33(1):17-28. PubMed ID: 36698323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.
    Yu Y; Yu X; Fan C; Wang H; Wang R; Feng C; Guan H
    J Mol Med (Berl); 2018 Aug; 96(8):777-790. PubMed ID: 29942976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
    Li J; Li X; Wu L; Pei M; Li H; Jiang Y
    Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
    Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
    J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.